[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pci\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pci":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,44,84,107,137,161,190,211,231],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100641201","intravascular-ultrasound-guidance-versus-angiography-guidance-in-patients-with-st-segment-elevation-myocardial-infarction-100641201",false,"NCT07616024","Intravascular Ultrasound guidaNce versuS angIoGrapHy Guidance in Patients With ST-segment Elevation Myocardial Infarction","Intravascular Ultrasound guidaNce versuS angIoGrapHy Guidance in Primary percuTaneous Coronary Intervention for Patients With ST-segment Elevation Myocardial Infarction","INSIGHT-STEMI","Inclusion criteria\n\n1. Patients diagnosed with acute ST-segment elevation myocardial infarction (STEMI) who have an indication for emergency interventional therapy;\n2. Subjects who are eligible to undergo primary percutaneous coronary intervention (PCI);\n3. Subjects or their authorized family members voluntarily agree to participate in the clinical trial and sign the written informed consent form;\n4. The IVUS catheter is expected to pass through the target lesion to complete the examination.\n\nExclusion Criteria\n\n1. Patients with cardiogenic shock or severe heart failure (Killip class IV);\n2. Patients who have previously undergone coronary artery bypass grafting (CABG);\n3. Patients with coma or disturbance of consciousness;\n4. Patients who are expected to be intolerant to long-term antiplatelet therapy;\n5. Pregnant women;\n6. Life expectancy \\\u003C 1 year;\n7. Currently participating in another drug\u002Fdevice clinical trial and not having reached the primary endpoint;\n8. Poor compliance, expected to be unable to complete follow-up.","ALL","18 Years",{"count":20,"type":21},2488,"ESTIMATED","INTERVENTIONAL",[24],"NA","STEMI represents the subtype of ACS with the worst prognosis, associated with high mortality and an elevated risk of complications. The use of IVI guidance holds the potential to reduce the incidence of MACE. In previous studies, there has been limited research on intravascular imaging in the context of primary revascularization procedures for STEMI, and no large-scale cohort study has compared the differences in clinical outcomes between IVI-guided and angiography-guided primary revascularization. Therefore, we conducted this large-scale randomized controlled trial to compare IVI-guided primary PCI versus coronary angiography-guided primary PCI in patients with STEMI.",[27,28],"STEMI","PCI",[27,28,30],"IVUS","NOT_YET_RECRUITING","2026-06-16",{"date":34,"type":35},"2026-06-18","ACTUAL",{"date":37,"type":21},"2026-06-01",{"date":39,"type":21},"2032-12-31",{"name":41,"class":42},"Shanghai Zhongshan Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":64,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":43},"100613651","surgical-versus-percutaneous-revascularization-in-patients-with-reduced-left-ventricular-function-stich-30-nl-100613651","NCT07269366","Surgical Versus Percutaneous Revascularization in Patients With Reduced Left Ventricular Function (STICH 3.0-NL)","Surgical Versus Percutaneous Revascularization in Patients With Reduced Left Ventricular Function","STICH 3*0-NL","Inclusion Criteria:\n\n* Age ≥ 18 years\n* LVEF≤ 40%\n* Angina pectoris, CCS≥2 and\u002For hospitalization for ACS or heart failure within 1 year prior to randomization\n* Multivessel CAD (2-3 vessel-disease with coronary lesions \\>70% and involvement of proximal LAD, and\u002For LM stenosis of \\>50%). Target vessels are determined by the local Heart Time\n* Clinical and angiographical characteristics suitable for isolated coronary revascularization both by CABG or PCI according to the judgment of the local Heart Team\n* Written informed consent\n\nExclusion Criteria:\n\n* ACS \\\u003C 48 hours before randomization\n* Valvular\u002Fstructural heart disease requiring intervention\n* Contra-indications to DAPT\n* Non-cardiac condition with life expectancy \\\u003C 1 year\n* Previous CABG\n* Decompensated HF at the time of inclusion",{"count":53,"type":21},358,[24],"This randomized multicenter trial compares coronary artery bypass grafting (CABG) with percutaneous coronary intervention (PCI) in 358 patients with ischemic left ventricular dysfunction and multivessel coronary disease. The study evaluates differences in survival, major cardiovascular events, and quality of life over 4 years, and contributes to the international STICH 3.0 collaboration assessing long-term outcomes.",[57,58,59,60,61,62,28,63],"Coronary Artery Disease","Coronary Artery Disease (CAD)","Multivessel Coronary Artery Disease","CABG","CABG in Low EF","Heart Failure","Revascularization",[65,66,67,68,69,70,71,72,73],"coronary artery","coronary artery disease","heart failure","low ejection fraction","hfref","cabg","coronary artery bypass graft","pci","revascularization","RECRUITING","2026-05-07",{"date":77,"type":35},"2026-05-12",{"date":79,"type":21},"2026-05",{"date":81,"type":21},"2034-05",{"name":83,"class":42},"University Medical Center Groningen",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100630703","the-cdac-study---cerebral-dysfunction-after-coronary-revascularization-100630703","NCT07491120","The CDAC Study - Cerebral Dysfunction After Coronary Revascularization","CDAC","Inclusion Criteria:\n\n* Criteria for enrollment are age 18 years or more.\n* A candidate for either elective single or multi-vessel CABG or PCI without limits for lesion location, lesion characteristics or complexity, the number of vessels treated, or the number of stents or bypass grafts placed, or the type of bypass grafts.\n* The decision to undergo either CABG or PCI will be made by the treating physician and patient before research study enrollment, and thus, the revascularization decision is not directed by this research protocol.\n\nExclusion Criteria:\n\nPatients will not be enrolled due to:\n\n* Concomitant valve therapy (surgical or transcatheter).\n* Prior CABG or surgical valve repair\u002Freplacement surgery.\n* PCI within 1 year of the study entry procedure.\n* A hybrid revascularization procedure (PCI plus CABG), an untreated carotid artery stenosis of \\>70%, inability to provide informed consent.\n* The inability to perform pre-procedure tablet-based neurocognitive testing.\n* The lack of stated agreement to return for follow-up on-site neurocognitive testing at the prescribed time points.",{"count":92,"type":21},600,"OBSERVATIONAL","Neurocognitive decline has long been suspected to be a potential long-term complication of coronary artery bypass grafting surgery (CABG), with reports of post-operative cognitive dysfunction by objective testing approaching 15-50% of patients in the year following surgery. To determine the true rate of long-term cognitive dysfunction following CABG compared to percutaneous coronary intervention (PCI or coronary stent placement), we propose a multi-center, two-group, non-randomized study using computer-based customized neurocognitive testing (Cogsate), prior to the procedure and then at 30 days, 1-year and 2-years after revascularization to evaluate cognitive function vital for the maintenance and advancement of professional and personal activities. It is anticipated that the study will document a higher rate of cognitive dysfunction in the CABG group, that the landmark study will provide both the patient and physician with the information necessary to make an informed decision regarding the cognitive risks of CABG versus PCI when faced with the need for coronary revascularization, and that these results will change the clinical practice of recommending CABG as a primary revascularization option for those wishing to preserve cognitive function.",[60,28,96],"Cognitive Decline",[60,28,96],"2026-03-19",{"date":100,"type":35},"2026-03-24",{"date":102,"type":21},"2027-01-01",{"date":104,"type":21},"2033-01-01",{"name":106,"class":42},"The Scripps Research Institute",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100600153","super-high-pressure-balloon-versus-intravascular-lithotripsy-to-prepare-severely-calcified-coronary-lesions-100600153","NCT07093788","Super High-pressure Balloon Versus Intravascular Lithotripsy to Prepare Severely Calcified Coronary Lesions","Super High-pressure Balloon Versus Intravascular Lithotripsy to Prepare Severely Calcified Coronary Lesions: a Randomized Controlled Trial (Shape)","Shape","Inclusion Criteria:\n\n* Age \\> 18 years and \\\u003C 80 years\n* Presented as asymptomatic angina, stable angina, unstable angina, prior myocardial infarction (MI), or non-ST-elevation myocardial infarction (NSTEMI).\n* Have an indication for drug-eluting stent (DES) implantation\n* Denovo coronary artery calcified lesions\n* Target lesion diameter stenosis ≥ 70%, or target lesion diameter stenosis between ≥ 50% and \\\u003C 70%, accompanied by evidence of myocardial ischemia(such as fractional flow reserve (FFR) ≤ 0.80 or minimal lumen area (MLA) ≤ 4.0 mm²).\n* Reference vessel diameter of the target vessel between 2.5 mm - 4.5 mm\n* Maximum calcium arc within the lesion ≥ 270⁰ assessed by optical coherence tomography (OCT) or intravascular ultrasound (IVUS)\n* Unsatisfactory lesion preparation with non-compliant balloon, defined as baseline diameter stenosis reduction of \\\u003C 30% under maximal inflation pressure.\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Presented as acute ST-segment elevation myocardial infarction (STEMI), cardiogenic shock and multiple organ failure\n* Presented as severe contrast agent allergy\n* Intolerant to dual antiplatelet therapy (DAPT) and\u002For anticoagulation therapy\n* Presented as active phase of autoimmune disease\n* Calcified nodules or eccentric calcification lesions\n* Failure to reach the target lesion with guidewires or catheters\n* Complex coronary bifurcation lesions\n* Target vessel thrombosis or aneurysm within 10 mm of the target lesion","80 Years",{"count":117,"type":21},78,[24],"this trial aimed to evaluate the stent expansion through intravascular imaging (optical coherence tomography (OCT) \\& intravascular ultrasound (IVUS)) among individuals underwent different preparation techniques ,then comparing the efficacy and safety of super high-pressure balloon to IVL in severely calcified lesions",[28,121,122],"Coronary Arterial Disease (CAD)","Calcified Coronary Lesions",[124,125,126],"super high-pressure balloon","percutaneous coronary intervention","intravascular lithotripsy","2026-03-06",{"date":129,"type":35},"2026-03-10",{"date":131,"type":35},"2025-09-01",{"date":133,"type":21},"2027-06-30",{"name":135,"class":42},"Nanjing First Hospital, Nanjing Medical University",3,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":115,"enrollmentInfo":144,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":146,"conditions":147,"keywords":150,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":43},"100615825","intravascular-imaging-guided-versus-angiography--guided-pci-in-patients-with-des-isr-100615825","NCT07297641","Intravascular Imaging-Guided Versus Angiography- Guided PCI in Patients With DES-ISR","Intravascular Imaging-Guided Versus Angiography- Guided Percutaneous Coronary Intervention for Drug-eluting In-stent Restenosis","Inclusion Criteria:\n\n(1) Patients with DES-ISR lesions; (2) Life expectancy of at least 1 year; (3) DES-ISR lesions occurring for the first time in native coronary arteries and suitable for re-PCI based on angiographic findings.\n\nExclusion Criteria:\n\n(1) Bare-metal stent in-stent restenosis (BMS-ISR). (2) Non-DES-ISR lesions. (3) Incomplete clinical and angiographic data. (4) Poor quality of IVUS or angiographic images. (5) Recurrent DES-ISR. (6) Optical coherence tomography (OCT) guidance.",{"count":145,"type":21},1500,"This study aimed to compare the clinical and angiographic outcomes of patients with DES-ISR who underwent repeat PCI with intravascular imaging or angiographic guidance.",[28,148,149],"In-stent Restenosis","Intravascular Imaging Device",[151,152,125],"in-stent restenosis","Intravascular imaging device","2025-12-09",{"date":155,"type":35},"2025-12-22",{"date":157,"type":21},"2026-01-01",{"date":159,"type":21},"2027-08-01",{"name":135,"class":42},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":173,"conditions":174,"keywords":178,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":186,"leadSponsor":188,"locationsCount":43},"100615461","phase-4-effect-of-empagliflozin-on-inflammation-100615461","NCT07292909","Effect of Empagliflozin on Inflammation","Randomized Trial to Evaluate the Anti-inflammatory Effects of Empagliflozin Following PCI","EMPANTINFLAM","Inclusion Criteria:\n\n* • Patients with stable CAD who are electively scheduled for PCI on a de novo lesion in a native coronary artery\n\nExclusion Criteria:\n\n* • Patients who have been taking an SGLT-2 inhibitor during the last month\n\n  * Patients who are receiving any anti-inflammatory medication: immunosuppressor, steroids, NSAID…\n  * Patients who have underlying inflammatory conditions such as rheumatic arthritis, infection, active malignancy\n  * Patients with an acute coronary syndrome within the last month\n  * Intervention on a restenotic lesion or lesion in a saphenous vein graft\n  * Creatinine clearance less than 30 mL\u002Fmin\n  * Patients who are treated with devices other than balloons and stents (lithotripsy, rotational atherectomy…)",{"count":170,"type":21},100,[172],"PHASE4","Empagliflozin is a drug given to lower glucose. It is used in the treatment of diabetes. However, it was shown to improve symptoms and survival of patients who are suffering from heart failure. The exact mechanism of this effect is currently not clearly understood.\n\nHe hypothesize that empagliflozin has other properties than glucose lowering, that can explain its efficacy. One of these properties, is an anti-inflammatory effect.\n\nTo document this, we are using a model of inflammation following percutaneous coronary scenting. We know that patients who get a stent will develop inflammation following stenting. This is documenting by a higher level of C-Reactive Protein 24 hours after the procedure.\n\nPatients who will participate in the study, will receive empagliflozin or a placebo tablet for 3 days prior to the revascularisation procedure. CRP and other inflammatory markers will be measured before intervention and 24 hours later. The goal is to demonstrate a lower rise in CRP following intervention in patients treated with empagliflozin vs. those who have received a placebo.",[175,176,28,177],"CAD - Coronary Artery Disease","Inflamation","SGLT 2 Inhibitors",[179,180,181],"CAD","inflammation","SGLT2 inhibitors","2025-12-06",{"date":184,"type":35},"2025-12-18",{"date":131,"type":35},{"date":187,"type":21},"2027-09-30",{"name":189,"class":42},"Hotel Dieu de France Hospital",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":4},"100608106","prognostic-role-of-lipoproteina-in-elective-percutaneous-coronary-revascularization-100608106","NCT07197242","Prognostic Role of Lipoprotein(a) in Elective Percutaneous Coronary Revascularization","Assessment of Lipoprotein(a) in Patients Undergoing Elective Percutaneous Coronary Revascularization: Implications for Cardiovascular Risk Stratification","Inclusion Criteria:\n\n* Adults aged 18 years or older\n\nUndergoing elective PCI for stable coronary artery disease\n\nAbility to provide informed consent\n\nWillingness to undergo blood sampling prior to PCI\n\nExclusion Criteria:\n\n* Acute coronary syndrome within 30 days\n\nCardiogenic shock\n\nPrior heart transplant or left ventricular assist device (LVAD)\n\nLife expectancy less than 1 year due to non-cardiac causes\n\nParticipation in a blinded Lp(a)-lowering outcome trial at the time of enrollment",{"count":198,"type":21},156,"The study investigates the role of Lipoprotein(a) \\[Lp(a)\\] levels in predicting cardiovascular risk and adverse events in patients undergoing elective percutaneous coronary intervention (PCI).",[28],[28,66],"2025-09-20",{"date":204,"type":35},"2025-09-29",{"date":206,"type":21},"2026-10-01",{"date":208,"type":21},"2027-12-30",{"name":210,"class":42},"Assiut University",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":43},"100592364","short-term-outcomes-after-primary-pci-in-diabetic-patients-treated-with-insulin-versus-oral-anti-diabetic-drugs-100592364","NCT06992466","Short Term Outcomes After Primary PCI in Diabetic Patients Treated With Insulin Versus Oral Anti-diabetic Drugs","Observ","Inclusion Criteria:\n\n* Patients with DM (type 2) undergoing primary PCI for STEMI.1-\n\nTreated with either insulin or OADs prior to admission.2-\n\n3- Age ≥18 year\n\nExclusion Criteria:\n\n* Type 1 DM.1- Patients on both insulin and OADs.2- 3-Prior coronary artery bypass graft (CABG) surgery. 4-Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²). 5-Hemodynamically unstable patients 6-moderate to severe VHD 7-Patients who were shifted from OADs to insulin during Follow-up",{"count":219,"type":21},210,"• This study aims to compare the short-term clinical and echocardiographic outcomes of primary PCI in diabetic patients treated with insulin versus OADs.",[222,28],"Diabetes Mellitus","2025-05-19",{"date":225,"type":35},"2025-05-28",{"date":227,"type":21},"2025-05-20",{"date":229,"type":21},"2026-02-25",{"name":210,"class":42},{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":249,"leadSponsor":251,"locationsCount":4},"100554447","advanced-coronary-plaque-morphology-assessment-using-photon-counting-detection-and-invasive-coronary-imaging-100554447","NCT06499207","Advanced Coronary Plaque Morphology Assessment Using Photon-counting Detection and Invasive Coronary Imaging","ACDC","Inclusion Criteria:\n\n* Signed written informed consent\n* DES in proximal coronary vessel segments\n\nExclusion Criteria:\n\n\\- Any conditions that may interfere with the safety or efficacy of CCTA",{"count":239,"type":21},25,[24],"This clinical trial aims to compare non-invasive photon-counting detector computed tomography (PCD-CT) with invasive intravascular imaging (IVI) for post-interventional follow-up in patients with coronary artery disease (CAD).\n\nParticipants will undergo post-interventional follow-up using both PCD-CT and coronary angiography with IVI. Researchers will test qualitative and quantitative PCD-CT results for non-inferiority to IVI regarding stent evaluation and detection of in-stent restenosis and plaque morphology.",[57,243,28,244],"Coronary Disease","Stent Restenosis","2024-11-18",{"date":247,"type":35},"2024-11-20",{"date":247,"type":21},{"date":250,"type":21},"2026-07-15",{"name":252,"class":42},"Medical University of Vienna"]